肿瘤预防与治疗2025，Vol.38Issue(12)：1105-1113,9.DOI:10.3969/j.issn.1674-0904.2025.12.010
免疫检查点抑制剂的内分泌毒性发生机制、研究进展与临床管理
Immune Checkpoint Inhibitor-Induced Endocrine Toxicity:Pathogenesis,Research Progress and Clinical Management
Niu Huihui 1Si Qinqin2
作者信息
- 1. Second Clinical College,Changzhi Medical College,Changzhi 046000,Shanxi,China
- 2. De-partment of Endocrinology,Heji Hospital Affiliated to Changzhi Medical College,Changzhi 046000,Shanxi,China
- 折叠
摘要
Abstract
Immune checkpoint inhibitors(ICIs)represent a fundamental approach in cancer immunotherapy and have ex-hibited substantial clinical efficacy across a spectrum of malignant tumors.The immune-related adverse events induced by ICIs,particularly endocrine toxicity,pose a significant clinical challenge.This article systematically reviews the epidemiolo-gy,pathogenesis,toxicity profiles,research progress and clinical management of ICI-induced endocrine toxicity.Further-more,it emphasizes the critical importance of early identification and multidisciplinary collaboration to balance antitumor effi-cacy with toxicity risks.关键词
免疫检查点抑制剂/内分泌毒性/发病机制/研究进展/临床管理/肿瘤/免疫治疗Key words
Immune checkpoint inhibitors/Endocrine toxicity/Pathogenesis/Research progress/Clinical management/Tumor/Immunotherapy分类
医药卫生引用本文复制引用
Niu Huihui,Si Qinqin..免疫检查点抑制剂的内分泌毒性发生机制、研究进展与临床管理[J].肿瘤预防与治疗,2025,38(12):1105-1113,9.
